Year |
Citation |
Score |
2018 |
Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. The Journal of Molecular Diagnostics : Jmd. PMID 29936259 DOI: 10.1016/J.Jmoldx.2018.05.004 |
0.362 |
|
2018 |
Lieber DS, White E, Silterra J, Zhong S, Brennan T, Coyne M, Kennedy M, Gandara DR, Kowanetz M, Paul SM, Schleifman E, Li Y, Rittmeyer A, Fehrenbacher L, Amler L, et al. Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A41 |
0.362 |
|
2018 |
Fabrizio D, Lieber D, Malboeuf C, Silterra J, White E, Coyne M, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, Cummings C, Peters E, et al. Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab Cancer Research. 78: 5706-5706. DOI: 10.1158/1538-7445.Am2018-5706 |
0.353 |
|
2018 |
Rittmeyer A, Gandara D, Kowanetz M, Mok T, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, et al. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) Pneumologie. 72: S49-S50. DOI: 10.1055/S-0037-1619250 |
0.302 |
|
2017 |
Lieber DS, Kennedy MR, Johnson DB, Greenbowe JR, Frampton GM, Schrock AB, Ross JS, Stephens PJ, Ali SM, Miller VA, Fabrizio DA. Abstract B16: Validation and clinical feasibility of a Foundation Medicine assay to identify immunotherapy response potential through tumor mutational burden (TMB) Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B16 |
0.405 |
|
2017 |
Lieber DS, Kennedy MR, Johnson DB, Rosenberg JE, Kowanetz M, Greenbowe JR, Frampton GM, Connelly CF, Schrock AB, Ross JS, Stephens PJ, Ali SM, Miller VA, Fabrizio DA. Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Cancer Research. 77: 2987-2987. DOI: 10.1158/1538-7445.Am2017-2987 |
0.418 |
|
2017 |
Gandara D, Kowanetz M, Mok T, Rittmeyer A, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, et al. Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) Annals of Oncology. 28: v460. DOI: 10.1093/Annonc/Mdx380 |
0.302 |
|
2017 |
Fabrizio D, Malboeuf C, Lieber D, Zhong S, He J, White E, Coyne M, Silterra J, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, et al. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) Annals of Oncology. 28: v27. DOI: 10.1093/Annonc/Mdx363.018 |
0.328 |
|
2016 |
Chennagiri N, White EJ, Frieden A, Lopez E, Lieber DS, Nikiforov A, Ross T, Batorsky R, Hansen S, Lip V, Luquette LJ, Mauceli E, Margulies D, Milos PM, Napolitano N, et al. Orthogonal NGS for High Throughput Clinical Diagnostics. Scientific Reports. 6: 24650. PMID 27090146 DOI: 10.1038/Srep24650 |
0.437 |
|
2014 |
Lieber DS, Hershman SG, Slate NG, Calvo SE, Sims KB, Schmahmann JD, Mootha VK. Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency. Bmc Medical Genetics. 15: 30. PMID 24602372 DOI: 10.1186/1471-2350-15-30 |
0.683 |
|
2013 |
Hildick-Smith GJ, Cooney JD, Garone C, Kremer LS, Haack TB, Thon JN, Miyata N, Lieber DS, Calvo SE, Akman HO, Yien YY, Huston NC, Branco DS, Shah DI, Freedman ML, et al. Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4. American Journal of Human Genetics. 93: 906-14. PMID 24119684 DOI: 10.1016/J.Ajhg.2013.09.011 |
0.654 |
|
2013 |
Caudy AA, Guan Y, Jia Y, Hansen C, DeSevo C, Hayes AP, Agee J, Alvarez-Dominguez JR, Arellano H, Barrett D, Bauerle C, Bisaria N, Bradley PH, Breunig JS, Bush E, ... ... Lieber D, et al. A new system for comparative functional genomics of Saccharomyces yeasts. Genetics. 195: 275-87. PMID 23852385 DOI: 10.1534/Genetics.113.152918 |
0.336 |
|
2013 |
Lieber DS, Calvo SE, Shanahan K, Slate NG, Liu S, Hershman SG, Gold NB, Chapman BA, Thorburn DR, Berry GT, Schmahmann JD, Borowsky ML, Mueller DM, Sims KB, Mootha VK. Targeted exome sequencing of suspected mitochondrial disorders. Neurology. 80: 1762-70. PMID 23596069 DOI: 10.1212/Wnl.0B013E3182918C40 |
0.717 |
|
2012 |
Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, Laskowski A, Garone C, Liu S, Jaffe DB, Christodoulou J, Fletcher JM, Bruno DL, Goldblatt J, Dimauro S, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Science Translational Medicine. 4: 118ra10. PMID 22277967 DOI: 10.1126/Scitranslmed.3003310 |
0.712 |
|
2012 |
Lieber DS, Vafai SB, Horton LC, Slate NG, Liu S, Borowsky ML, Calvo SE, Schmahmann JD, Mootha VK. Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease. Bmc Medical Genetics. 13: 3. PMID 22226368 DOI: 10.1186/1471-2350-13-3 |
0.705 |
|
2012 |
Lieber DS, Calvo SE, Slate NG, Liu S, Borowsky ML, Hershman SG, Gold NB, Berry GT, Mueller DM, Schmahmann JD, Sims KB, Mootha VK. Targeted exome sequencing of suspected mitochondrial disorders in a hospital-based cohort Mitochondrion. 12: 575-576. DOI: 10.1016/J.Mito.2012.07.065 |
0.706 |
|
Show low-probability matches. |